Tag: investing
-
AstraZeneca Keeps Its $80 Billion Goal Despite a Major Trial Setback
AstraZeneca reaffirmed its $80 billion revenue ambition after reporting solid second-quarter results. Strong oncology and rare disease sales helped restore confidence following the failure of a major Wainua trial.
-
Why Big Pharma Is Buying Biotech Again: The Patent Cliff Explained
Patent expirations are reshaping the pharmaceutical industry. Here’s why Big Pharma is buying biotech companies again—and what investors should watch next.
-
Pfizer Lands Metsera Acquisition After Novo Nordisk Bows Out of $10 B Bidding War
Pfizer’s acquisition of Metsera secures a high-potential obesity-drug pipeline — but because Metsera’s assets are early-stage, the deal carries meaningful regulatory and execution risk.
-
Bidding War Heats Up: Pfizer vs. Novo Nordisk in the Race to Acquire Metsera
The intense bidding war between Pfizer and Novo Nordisk over Metsera underscores just how fiercely the global obesity-drug market is being contested.